



For immediate release 7.00am: 14 April 2016

HVIVO PLC
("hVIVO" or the "Company")

Directors' Dealings

hVIVO plc (AIM: HVO), the pioneer of human disease models, announces that application has been made to AIM for the admission of 9,935 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase \$20,000 and £4,000 of hVIVO plc new ordinary shares respectively per quarter. The New Ordinary Shares represent their investments for the quarter ended 31 March 2016. On 13 April 2016, Mr Ellertson invested in an additional 7,731 ordinary shares and Mr Winschel invested in an additional 2,204 ordinary shares, at a price of 181.5 pence per share.

Following admission of the 9,935 New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,070,239 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 19 April 2016. Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 38,693 and 30,340 ordinary shares of 5.0p in the Company respectively, each representing less than 0.1% of the Company's issued share capital.

For further information please contact:

hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including RSV, flu, asthma, and common cold. hVIVO has commercialised four disease models, successfully enrolled over 2,100 subjects and conducted over 40 product validation studies for a wide range of industry, government and academic clients and collaborators.